ToolsProjection · SURMOUNT-1 data
Tirzepatide Weight-Loss Projection Calculator
Explore the SURMOUNT-1 group averages
Enter a starting weight and a trial dose group to illustrate the average 72-week change reported in SURMOUNT-1. This is a trial-based illustration, not a personal prediction or a dose recommendation.
Individual results vary. The trial included structured titration and lifestyle support. Tirzepatide requires a prescription; discuss treatment and realistic expectations with a licensed clinician.
Enter your current weight to see a SURMOUNT-1-based projection.
How it is projected. The tool multiplies your starting weight by the SURMOUNT-1 mean total-body-weight reduction at 72 weeks for the dose you pick (5 mg ≈ −15.0%, 10 mg ≈ −19.5%, 15 mg ≈ −20.9%; Jastreboff et al., NEJM 2022, PMID 35658024), then subtracts that from your starting weight. The milestone rows distribute that same total across an illustrative early-fast / late-plateau curve. Worked example: 250 lb at 15 mg → −20.9% = 52 lb lost → ~198 lb. These are averages from a trial that paired the drug with structured titration and lifestyle support; individual outcomes vary widely.
How to interpret this projection
Enter your current weight and a maintenance dose, and this tool projects roughly where the average SURMOUNT-1 participant landed at 72 weeks — the phase 3 obesity trial of tirzepatide (the molecule in Zepbound and Mounjaro). It applies that trial’s mean total-body-weight reductions (5 mg ≈ −15%, 10 mg ≈ −19.5%, 15 mg ≈ −20.9%) to your number. It is a trial-average projection, not a personal prediction — the dose only looks up an average result.
Limits of the illustration
This is a projection based on clinical-trial group averages — not a promise, a personal prediction, or medical advice. SURMOUNT-1 reported mean weight loss; real individuals lost much more or much less, and the trial combined the drug with structured dose titration and lifestyle support. The tool does not recommend a dose, predict your individual response, or account for your health history, medications, side effects, or whether you can tolerate or stay on the drug. Tirzepatide is prescription-only; talk to a licensed clinician about whether it is right for you and what results are realistic.
Where to get it
Getting to the maintenance dose
SURMOUNT-1 results assume you reach and hold a maintenance dose for ~72 weeks. These programs hold one price across every dose level.
CoreAge Rx
Compounded tirzepatide starting offer with order-stage and 30-day refund limits.
From $129/mo; confirm term and supplyCompounded tirzepatide
Found
Medication-specific four-week plans with separate cash, clinical-insurance and branded routes.
Cash $219 intro; then $359/4 weeksCompounded tirzepatide and brand-name GLP-1 options
Gala Health
Compounded GLP-1 options with yearly and three-month price labels to compare.
$179/mo yearly label; $199/mo 3-month offerCompounded GLP-1/GIP, including tirzepatide
We may earn a commission at no extra cost to you. Affiliate partners appear first. Disclosure
Frequently asked
- How accurate is this tirzepatide weight-loss projection?
- It is not a personal prediction. It applies the SURMOUNT-1 trial's mean (average) total-body-weight reduction at 72 weeks to your starting weight: about -15.0% at 5 mg, -19.5% at 10 mg, and -20.9% at 15 mg. Individual results in the trial ranged widely above and below those averages, and the trial paired the drug with dose titration and lifestyle support. Treat the number as a population average, not a guarantee.
- Where do the percentages come from?
- They are the mean percentage changes in body weight at week 72 from SURMOUNT-1, the phase 3 obesity trial of tirzepatide (Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022; PMID 35658024).
- Why does the calculator show a week-by-week trajectory?
- Weight loss on tirzepatide is steep early and tapers toward a plateau near 72 weeks. The milestone rows distribute each dose's 72-week mean across an illustrative early-fast, late-plateau curve so the shape is realistic. The intermediate weeks are an illustrative curve, not separate trial endpoints.
- Does this tell me which dose to take?
- No. The dose selector only looks up the trial's mean result at that maintenance dose. It is not a dose recommendation. Tirzepatide is prescription-only and is titrated under clinician supervision; talk to a licensed provider about what is appropriate for you.
Understand the numbers before you set expectations
A projected number is the easy part. How the trials actually ran, how dosing is titrated, and what real results look like are what set honest expectations — read these next:
This calculator is informational and not medical advice. It performs simple arithmetic (projected weight = current weight × (1 − the SURMOUNT-1 mean reduction for the chosen dose)) and makes no judgment about what you will personally lose, what dose is right for you, or whether tirzepatide is appropriate. Clinical-trial averages are achieved under trial conditions and do not predict any one person’s outcome. Tirzepatide is available by prescription after clinician review.